Biozipcode, Inc.
| Company Name | Biozipcode, Inc. |
| Established | January 2022 |
| Capital | JPY 70 million |
| Head Office | 2F-C, Shibuya Dogenzaka Tokyu Building, 1-10-8 Dogenzaka, Shibuya-ku, Tokyo 150-0043, Japan |
| Representative | Representative Director Fumihisa Kojima |
| Principal Business Activities |
|
LAB TO LIFE
Bringing university research into care that reaches patients.
Biozipcode, Inc. is a research-driven biotech company built on joint research with universities. We aim to turn research findings into new diagnostic and therapeutic technologies for use in healthcare.
Our research and development focuses on diabetes stem cell research into abnormal hematopoietic stem cells thought to contribute to the difficulty of treating diabetes, and on Biozipcode™ cell-targeting technology, which uses short peptides that recognize specific cells and tissues.
Our role goes beyond publishing research findings. We develop them into intellectual property, diagnostic technologies, therapeutic candidates, and medical materials, and work with pharmaceutical companies, research institutions, and healthcare providers to bring them into clinical use.
RESEARCH COLLABORATION
Joint Research with Kyoto University
Since April 2026, we have been conducting joint research with Kyoto University’s industry–academia joint research department, the Department of Biocommunication Development.
Our research theme is “Development of Cell-Targeted Therapies”, aiming to develop new diagnostic and therapeutic technologies for difficult-to-treat conditions, including diabetes and cancer, by applying technology that selectively recognizes cells and tissues.
We connect academic research at the university with our work in intellectual property, business development, clinical development, manufacturing partnerships, and regulatory affairs to bring research findings into practical use.
From Science to Better Care.
To bring research into real-world use, we work with pharmaceutical companies, research institutions, healthcare providers, businesses, investors, and supporters in Japan and abroad.
About Us
Grounded in diabetes stem cell research and Biozipcode™ cell-targeting technology, we work toward treatments that address the roots of hard-to-treat diseases and new approaches to care.
We work with pharmaceutical companies, research organizations, healthcare providers, and investors to advance new treatments through collaborative research, out-licensing, and co-development.
We work to take discoveries made at universities beyond the lab and develop them into diagnostic and therapeutic technologies that reach patients.
A research-driven biotech company built on joint research with universities, translating scientific findings into new diagnostic and therapeutic technologies for real-world use.
Our team brings together expertise in medicine, life sciences, information science, and business development to advance projects from basic research toward real-world applications.
Find the locations of Biozipcode, Inc. and our collaborative research sites. Please check the access information for each site before visiting.
